Sign up to save your podcasts
Or
Share Under the Radar: What should we know about Italian pharmaceutical giant Menarini’s growth story in APAC and how important are partnerships to the firm?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Under the Radar: What should we know about Italian pharmaceutical giant Menarini’s growth story in APAC and how important are partnerships to the firm?
Today we’re going to bring you an inside look into an Italian pharmaceutical firm with over 135 years of history.
Founded in 1886 in Naples under the name of Farmacia Internazionale, our guest for today is from Menarini Group, a leading pharmaceutical and diagnostics company with a presence in over 140 countries.
The firm prides itself as a leading provider of important healthcare brands, with its 18 manufacturing plants producing over 609 million packets of products a year.
To this end, Menarini said it operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields.
That includes Consumer Health, Dermatology, Allergy or Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology or Specialty Care and more.
All in, Menarini reported consolidated turnover of 4.375 billion euros in 2023, with international markets contributing 79% to the numbers. But how much of this is contributed by demand from the Asia-Pacific region?
Meanwhile, Menarini is also seeing a number of interesting developments of late. For one thing, Menarini APAC had in June 2024 expanded its partnership with Pharmacosmos to tackle iron deficiency in patients in Singapore and Malaysia.
So just how important are such licensing deals and partnerships in helping Menarini broaden its offerings while lowering R&D costs?
On Under the Radar, Money Matters’ finance presenter Chua Tian Tian posed these questions to Glen Godresse, CEO, Menarini APAC.
See omnystudio.com/listener for privacy information.
View all episodes
By MONEY FM 89.3Today we’re going to bring you an inside look into an Italian pharmaceutical firm with over 135 years of history.
Founded in 1886 in Naples under the name of Farmacia Internazionale, our guest for today is from Menarini Group, a leading pharmaceutical and diagnostics company with a presence in over 140 countries.
The firm prides itself as a leading provider of important healthcare brands, with its 18 manufacturing plants producing over 609 million packets of products a year.
To this end, Menarini said it operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields.
That includes Consumer Health, Dermatology, Allergy or Respiratory, Gastroenterology, Cardio-metabolic, Anti-infectives, Oncology or Specialty Care and more.
All in, Menarini reported consolidated turnover of 4.375 billion euros in 2023, with international markets contributing 79% to the numbers. But how much of this is contributed by demand from the Asia-Pacific region?
Meanwhile, Menarini is also seeing a number of interesting developments of late. For one thing, Menarini APAC had in June 2024 expanded its partnership with Pharmacosmos to tackle iron deficiency in patients in Singapore and Malaysia.
So just how important are such licensing deals and partnerships in helping Menarini broaden its offerings while lowering R&D costs?
On Under the Radar, Money Matters’ finance presenter Chua Tian Tian posed these questions to Glen Godresse, CEO, Menarini APAC.
See omnystudio.com/listener for privacy information.
More shows like Money Matters with Hongbin Jeong and Chua Tian Tian
View all
Global News Podcast
7,659 Listeners
Economist Podcasts
4,214 Listeners
Motley Fool Money
3,177 Listeners
Fareed Zakaria GPS
3,410 Listeners
WSJ Minute Briefing
661 Listeners
Wall Street Breakfast
1,022 Listeners
Yah Lah But
14 Listeners
Behind the Money
221 Listeners
FT News Briefing
678 Listeners
Breakfast with Ryan Huang, Emaad Akhtar and Audrey Siek
0 Listeners
Your Money with Michelle Martin
1 Listeners
The Daily Ketchup
7 Listeners
The Global Story
133 Listeners
Stock Movers
28 Listeners
Swamp Notes
21 Listeners